Glutamate and Schizophrenia: Phencyclidine, N‐Methyl‐d‐Aspartate Receptors, and Dopamine–Glutamate Interactions
The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Disorders of attention and perception in early schizophrenia
McGHIE, A., & CHAPMAN, J. (1961) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1961.tb00936.x · Cited by 1,188
Neuropsychological Function in Schizophrenia: Selective Impairment in Memory and Learning
Saykin, A. J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810310036007 · Cited by 1,155
David Smith, A., & Paul Bolam, J. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90106-k · Cited by 1,036
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens
Nicola, S. M., Surmeier, D. J., & Malenka, R. C. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.185 · Cited by 931
Neuropsychology of First-Episode Schizophrenia: Initial Characterization and Clinical Correlates
Bilder, R. M., Goldman, R. S., Robinson, D., Reiter, G., Bell, L., Bates, J. A., Pappadopulos, E., Willson, D. F., Alvir, J. M. J., Woerner, M. G., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.549 · Cited by 906
Chumakov, I., Blumenfeld, M., Guerassimenko, O., Cavarec, L., Palicio, M., Abderrahim, H., Bougueleret, L., Barry, C., Tanaka, H., La Rosa, P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412499 · Cited by 829
Prefrontal neurons and the genetics of schizophrenia
Weinberger, D. R., Egan, M. F., Bertolino, A., Callicott, J. H., Mattay, V. S., Lipska, B. K., Berman, K. F., & Goldberg, T. E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01252-5 · Cited by 741
Prefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724
Increased dopamine transmission in schizophrenia: relationship to illness phases
Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., & Innis, R. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00067-0 · Cited by 715
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET
Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997) · Nature · doi:10.1038/385634a0 · Cited by 710
Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits
Chatterton, J. E., Awobuluyi, M., Premkumar, L. S., Takahashi, H., Talantova, M., Shin, Y., Cui, J., Tu, S., Sevarino, K. A., Nakanishi, N., et al. (2002) · Nature · doi:10.1038/nature715 · Cited by 694
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Effects of Ketamine in Normal and Schizophrenic Volunteers
Lahti, A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00243-3 · Cited by 674
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
Lieberman, J. A., Perkins, D., Belger, A., Chakos, M., Jarskog, F., Boteva, K., & Gilmore, J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01303-8 · Cited by 593
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1139 · Cited by 583
Self-citationD-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia
Hahn, C.-G., Wang, H.-Y., Cho, D.-S., Talbot, K., Gur, R. E., Berrettini, W. H., Bakshi, K., Kamins, J., Borgmann-Winter, K. E., Siegel, S. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1418 · Cited by 563
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo
Do, K. Q., Trabesinger, A. H., Kirsten‐Krüger, M., Lauer, C. J., Dydak, U., Hell, D., Holsboer, F., Boesiger, P., & Cuénod, M. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00229.x · Cited by 540
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 490
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Self-citationBaseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia
Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindström, L. H., & Engberg, G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02242-x · Cited by 471
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains
Torrey, E. F., Barci, B. M., Webster, M. J., Bartko, J. J., Meador-Woodruff, J. H., & Knable, M. B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.019 · Cited by 426
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
Bringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403
Tseng, K. Y., & O'Donnell, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1021-04.2004 · Cited by 402
Jentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
Cosford, N. D. P., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm025570j · Cited by 396
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Self-citationKegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Early-stage visual processing and cortical amplification deficits in schizophrenia
Butler, P. D., Zemon, V., Schechter, I., Saperstein, A. M., Hoptman, M. J., Lim, K. O., Revheim, N., Silipo, G., & Javitt, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.5.495 · Cited by 362
Self-citationDopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum
Cepeda, C., & Levine, M. S. (1998) · Developmental Neuroscience · doi:10.1159/000017294 · Cited by 351
Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Adler, C. M., Malhotra, A. K., Elman, I., Goldberg, T., Egan, M., Pickar, D., & Breier, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.10.1646 · Cited by 337
SPECT imaging of striatal dopamine release after amphetamine challenge.
Laruelle, M. A., Abi‐Dargham, A., van Dyck, C. H., Rosenblatt, W., Zea‐Ponce, Y., Zoghbi, S. S., Baldwin, R. M., Charney, D. S., Hoffer, P. B., & Kung, H. F. (1995) · PubMed · Cited by 333
Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4722-05.2006 · Cited by 329
Impact of complex genetic variation in COMT on human brain function
Meyer-Lindenberg, A., Nichols, T., Callicott, J. H., Ding, J., Kolachana, B., Buckholtz, J., Mattay, V. S., Egan, M., & Weinberger, D. R. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001860 · Cited by 319
MacDonald, A. W., Carter, C. S., Kerns, J. G., Ursu, S., Barch, D. M., Holmes, A. J., Stenger, V. A., & Cohen, J. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.475 · Cited by 318
Krystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
Schumacher, J., Abon Jamra, R., Freudenberg, J., Becker, T., Ohlraun, S., Otte, A. C. J., Tullius, M., Kovalenko, S., Van Den Bogaert, A., Maier, W., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001421 · Cited by 312
d-Cycloserine: A ligand for the coupled glycine receptor has partial agonist characteristics
Hood, W. F., Compton, R. P., & Monahan, J. B. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90379-0 · Cited by 308
Miyamoto, E. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.cpj06007x · Cited by 302
Longitudinal Study of Cognitive Function in First-Episode and Recent-Onset Schizophrenia
Gold, S., Arndt, S., Nopoulos, P., O’Leary, D. S., & Andreasen, N. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1342 · Cited by 296
The Metabotropic Glutamate Receptors: Structure, Activation Mechanism and Pharmacology
Pin, J.-P., & Acher, F. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007023339328 · Cited by 294
Imaging dopamine transmission in schizophrenia. A review and meta-analysis.
Laruelle, M. (1998) · PubMed · Cited by 281
Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers
Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300342 · Cited by 277
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
MODEL PSYCHOSES AND SCHIZOPHRENIA
LUBY, E. D., GOTTLIEB, J. S., COHEN, B. D., ROSENBAUM, G., & DOMINO, E. F. (1962) · American Journal of Psychiatry · doi:10.1176/ajp.119.1.61 · Cited by 268
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Self-citationWest, A. R., & Grace, A. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00294.2002 · Cited by 253
The involvement of ErbB4 with schizophrenia: Association and expression studies
Silberberg, G., Darvasi, A., Pinkas‐Kramarski, R., & Navon, R. (2006) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30275 · Cited by 251
Tanaka, H., Grooms, S. Y., Bennett, M. V. L., & Zukin, R. S. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02951-6 · Cited by 242
Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Self-citationShurman, B., Horan, W. P., & Nuechterlein, K. H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.020 · Cited by 237
Chen, L., Muhlhauser, M., & Yang, C. R. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00680.2002 · Cited by 230
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Vollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Heidinger, V., Manzerra, P., Wang, X. Q., Strasser, U., Yu, S.-P., Choi, D. W., & Behrens, M. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05452.2002 · Cited by 223
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Self-citationBarch, D. M., & Carter, C. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.019 · Cited by 222
Depoortère, R., Dargazanli, G., Estenne-Bouhtou, G., Coste, A., Lanneau, C., Desvignes, C., Poncelet, M., Heaulme, M., Santucci, V., Decobert, M., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300772 · Cited by 220
Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J., & Conn, P. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219
Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson' disease
Starr, M. S. (1995) · Synapse · doi:10.1002/syn.890190405 · Cited by 214
Enhancement by an Ampakine of Memory Encoding in Humans
Ingvar, M., Ambros-Ingerson, J., Davis, M., Granger, R., Kessler, M., Rogers, G. A., Schehr, R. S., & Lynch, G. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6581 · Cited by 211
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
Tuominen, H. J., Tiihonen, J., & Wahlbeck, K. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.005 · Cited by 209
A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia
Goff, D. C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A. C., Johnson, S. A., & Lynch, G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00005 · Cited by 209
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Abdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206
Facilitated Glutamatergic Transmission in the Striatum of D2Dopamine Receptor-Deficient Mice
Cepeda, C., Hurst, R. S., Altemus, K. L., Flores-Hernández, J., Calvert, C. R., Jokel, E. S., Grandy, D. K., Low, M. J., Rubinstein, M., Ariano, M. A., et al. (2001) · Journal of Neurophysiology · doi:10.1152/jn.2001.85.2.659 · Cited by 203
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201
Smith, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00092-4 · Cited by 201
Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine
Malhotra, A. K., Adler, C. M., Kennison, S. D., Elman, I., Pickar, D., & Breier, A. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00546-x · Cited by 200
Adjunctive high-dose glycine in the treatment of schizophrenia
Javitt, D. C., Silipo, G., Cienfuegos, A., Shelley, A.-M., Bark, N., Park, M., Lindenmayer, J.-P., Suckow, R., & Zukin, S. R. (2001) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002590 · Cited by 199
Self-citationLachman, H. M., Nolan, K. A., Mohr, P., Saito, T., & Volavka, J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.835 · Cited by 198
The Neurochemical Circuitry of Schizophrenia
Carlsson, A. (2006) · Pharmacopsychiatry · doi:10.1055/s-2006-931483 · Cited by 197
Benquet, P., Gee, C. E., & Gerber, U. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09679.2002 · Cited by 196
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype
Tsai, G., Ralph-Williams, R. J., Martina, M., Bergeron, R., Berger-Sweeney, J., Dunham, K. S., Jiang, Z., Caine, S. B., & Coyle, J. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402662101 · Cited by 190
Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum
Kötter, R. (1994) · Progress in Neurobiology · doi:10.1016/0301-0082(94)90037-x · Cited by 186
Korostishevsky, M., Kaganovich, M., Cholostoy, A., Ashkenazi, M., Ratner, Y., Dahary, D., Bernstein, J., Bening-Abu-Shach, U., Ben-Asher, E., Lancet, D., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.04.006 · Cited by 186
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Lane, H.-Y., Huang, C.-L., Wu, P.-L., Liu, Y.-C., Chang, Y.-C., Lin, P.-Y., Chen, P.-W., & Tsai, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.005 · Cited by 179
Goff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178
Steullet, P., Neijt, H. C., Cuénod, M., & Do, K. Q. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2005.10.014 · Cited by 173
Word and Tone Working Memory Deficits in Schizophrenia
Wexler, B. E., Stevens, A. A., Bowers, A. A., Sernyak, M. J., & Goldman-Rakic, P. S. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1093 · Cited by 173
Auditory Sensory Dysfunction in Schizophrenia: Imprecision or Distractibility?
Rabinowicz, E. F., Silipo, G., Goldman, R., & Javitt, D. C. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.12.1149 · Cited by 173
Self-citationPET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia
Karlsson, P., Farde, L., Halldin, C., & Sedvall, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.761 · Cited by 172
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Kinney, G. G., Sur, C., Burno, M., Mallorga, P. J., Williams, J. B., Figueroa, D. J., Wittmann, M., Lemaire, W., & Conn, P. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07586.2003 · Cited by 172
Reynolds, G. P., Abdul-Monim, Z., Neill, J. C., & Zhang, Z. (2004) · Neurotoxicity Research · doi:10.1007/bf03033297 · Cited by 171
Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users
Narendran, R., Frankle, W. G., Keefe, R., Gil, R., Martinez, D., Slifstein, M., Kegeles, L. S., Talbot, P. S., Huang, Y., Hwang, D.-R., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.12.2352 · Cited by 171
Sumiyoshi, T., Anil, A. E., Jin, D., Jayathilake, K., Lee, M., & Meltzer, H. Y. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003900 · Cited by 169
Martina, M., Gorfinkel, Y., Halman, S., Lowe, J. A., Periyalwar, P., Schmidt, C. J., & Bergeron, R. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.063321 · Cited by 167
Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans
Rowland, L. M., Astur, R. S., Jung, R. E., Bustillo, J. R., Lauriello, J., & Yeo, R. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300642 · Cited by 167
Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167
Self-citationLipina, T., Labrie, V., Weiner, I., & Roder, J. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2210-x · Cited by 159
Hampson, R. E., Rogers, G., Lynch, G., & Deadwyler, S. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02740.1998 · Cited by 153
Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats
Pilc, A., Kłodzińska, A., Brański, P., Nowak, G., Pałucha, A., Szewczyk, B., Tatarczyńska, E., Chojnacka-Wójcik, E., & Wierońska, J. M. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00082-5 · Cited by 150
Henry, S., Lehmann-Masten, V., Gasparini, F., Geyer, M. A., & Markou, A. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00332-5 · Cited by 149
Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs
Leveque, J.-C., Macı́as, W., Rajadhyaksha, A., Carlson, R. R., Barczak, A., Kang, S., Li, X.-M., Coyle, J. T., Huganir, R. L., Heckers, S., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04011.2000 · Cited by 148
Dopamine-mediated regulation of striatal neuronal and network interactions
Onn, S., West, A. R., & Grace, A. A. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00020-3 · Cited by 147
Elevated Homocysteine Levels in Young Male Patients With Schizophrenia
Levine, J., Stahl, Z., Sela, B. A., Gavendo, S., Ruderman, V., & Belmaker, R. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1790 · Cited by 147
Miller, D. W., & Abercrombie, E. D. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02144-2 · Cited by 146
The G72/G30 Gene Complex and Cognitive Abnormalities in Schizophrenia
Goldberg, T. E., Straub, R. E., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bigelow, L. B., Coppola, R., Egan, M. F., & Weinberger, D. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301049 · Cited by 142
Javitt, D. C., Duncan, L., Balla, A., & Sershen, H. W. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001552 · Cited by 138
Self-citationYee, B. K., Balic, E., Singer, P., Schwerdel, C., Grampp, T., Gabernet, L., Knuesel, I., Benke, D., Feldon, J., Mohler, H., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5120-05.2006 · Cited by 137
Where Do You Think You Are Going? The NMDA-D1 Receptor Trap
Cepeda, C., & Levine, M. S. (2006) · Science's STKE · doi:10.1126/stke.3332006pe20 · Cited by 136
Dursun, S. M., & Deakin, J. F. W. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500409 · Cited by 125
Cartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · Psychopharmacology · doi:10.1007/s002130050072 · Cited by 121
Auditory sensory ("echoic") memory dysfunction in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1517 · Cited by 121
Hartvig, P., Valtysson, J., Lindner, K.-J., Kristensen, J., Karlsten, R., Gustafsson, L. L., Persson, J., Svensson, J. O., Øye, I., Antoni, G., et al. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90194-9 · Cited by 119
Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum
Kulagina, N. V., Zigmond, M. J., & Michael, A. C. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00480-2 · Cited by 118
Hampson, R. E., Rogers, G., Lynch, G., & Deadwyler, S. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02748.1998 · Cited by 117
Dopamine is not Required for the Hyperlocomotor Response to NMDA Receptor Antagonists
Chartoff, E. H., Heusner, C. L., & Palmiter, R. D. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300678 · Cited by 116
Paquet, M., & Smith, Y. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07659.2003 · Cited by 115
Pen, G. L., Kew, J. N. C., Alberati, D., Borroni, E., Heitz, M., & Moreau, J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00374-3 · Cited by 112
Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L. M., & Curran, H. V. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1656-y · Cited by 111
Javitt, D. C., Balla, A., Burch, S., Suckow, R. F., Xie, S., & Sershen, H. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300313 · Cited by 108
Self-citationDistribution of mGluR1α and mGluR5 immunolabeling in primate prefrontal cortex
Muly, E. C., Maddox, M., & Smith, Y. (2003) · Journal of Comparative Neurology · doi:10.1002/cne.10937 · Cited by 108
Tsukada, H., Nishiyama, S., Fukumoto, D., Sato, K., Kakiuchi, T., & Domino, E. F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300732 · Cited by 108
Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man
Aalto, S., Ihalainen, J. A., Hirvonen, J., Kajander, J., Scheinin, H., Tanila, H., Någren, K., Vilkman, H., Gustafsson, L. L., Syvälahti, E. K. G., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0092-6 · Cited by 107
Kremer, I., Vass, Á., Gorelik, I., Bar, G., Blanaru, M., Javitt, D. C., & Heresco‐Levy, U. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.029 · Cited by 107
Self-citationDickinson, D., Ragland, J., Calkins, M., Gold, J., & Gur, R. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.003 · Cited by 106
Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 104
Self-citationTarget‐Specific Glutamatergic Regulation of Dopamine Neurons in the Ventral Tegmental Area
Takahata, R., & Moghaddam, B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751775.x · Cited by 101
Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?
Schoepp, D., & Marek, G. (2002) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007024606177 · Cited by 100
The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study
Hársing, L. G., Gacsályi, I., Szabo, G., Schmidt, E., Sziray, N., Sebban, C., Tesolin-Decros, B., Mátyus, P., Egyed, A., Spedding, M., et al. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)01078-x · Cited by 100
Glutamate receptor ligands as anxiolytics.
Chojnacka-Wójcik, E., Kłodzińska, A., & Pilc, A. (2001) · PubMed · Cited by 99
Itokawa, M., Yamada, K., Yoshitsugu, K., Toyota, T., Suga, T., Ohba, H., Watanabe, A., Hattori, E., Shimizu, H., Kumakura, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00006 · Cited by 98
The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers
Parwani, A., Weiler, M. A., Blaxton, T. A., Warfel, D. T., Hardin, M. G., Frey, K., & Lahti, A. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0177-2 · Cited by 98
Schizophrenia and impaired homocysteine metabolism: a possible association
Susser, E., Brown, A. S., Klonowski, E., Allen, R. H., & Lindenbaum, J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00427-7 · Cited by 97
Radant, A. D., Bowdle, T. A., Cowley, D. S., Kharasch, E. D., & Roy-Byrne, P. P. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00030-x · Cited by 97
Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia
Dursun, S. M., McIntosh, D., & Milliken, H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.10.950 · Cited by 96
Discovery and SAR of Org 24598—A Selective Glycine Uptake Inhibitor
Brown, A. R., Carlyle, I., Clark, J., Hamilton, W. D., GIBSON, S. G., McGarry, G., McEachen, S., Rae, D. R., Thorn, S. N., & Walker, G. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00355-9 · Cited by 95
NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans
Kegeles, L. S., Martinez, D., Kochan, L. D., Hwang, D., Huang, Y., Mawlawi, O., Suckow, R. F., Van Heertum, R. L., & Laruelle, M. (2002) · Synapse · doi:10.1002/syn.10010 · Cited by 94
Disruption of prepulse inhibition in mice lacking mGluR1
Brody, S. A., Conquet, F., & Geyer, M. A. (2003) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2003.03073.x · Cited by 94
Aubrey, K. R., & Vandenberg, R. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704381 · Cited by 94
van Berckel, B. N. M., Evenblij, C. N., van Loon, B. J., Maas, M. F., van der Geld, M. A. M., Wynne, H. J. A., van Ree, J. M., & Kahn, R. S. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00014-7 · Cited by 93
Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression
Gabernet, L., Pauly-Evers, M., Schwerdel, C., Lentz, M., Bluethmann, H., Vogt, K. E., Alberati, D., Möhler, H., & Boison, D. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.09.064 · Cited by 88
Synergistic Interactions between Ampakines and Antipsychotic Drugs
Johnson, S. A., Luu, N. T., Herbst, T. A., Knapp, R., Lutz, D., Arai, A., Rogers, G. A., & Lynch, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38148-0 · Cited by 85
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Silipo, G., & Shimoni, J. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798001242 · Cited by 85
Self-citationThe NMDA/D1 Receptor Complex as a New Target in Drug Development
Missale, C., Fiorentini, C., Busi, C., Collo, G., & Spano, P. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777057562 · Cited by 84
Balla, A., Sershen, H. W., Serra, M., Koneru, R., & Javitt, D. C. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300019 · Cited by 77
Self-citationHoney, R. A. E., Turner, D. C., Honey, G. D., Sharar, S. R., Kumaran, D., Pomarol-Clotet, E., McKenna, P., Sahakian, B. J., Robbins, T. W., & Fletcher, P. C. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300272 · Cited by 75
Glutamate pharmacology and the treatment of schizophrenia: current status and future directions
Tamminga, C. A., Holcomb, H. H., Gao, X. M., & Lahti, A. C. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199509000-00005 · Cited by 74
Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics
Evins, A. E., Amico, E. T., Shih, V., & GOFF, D. C. (1997) · Journal of Neural Transmission · doi:10.1007/bf01291892 · Cited by 74
Javitt, D. C., Sershen, H., Hashim, A., & Lajtha, A. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00047-x · Cited by 74
Self-citationEhlis, A., Reif, A., Herrmann, M. J., Lesch, K., & Fallgatter, A. J. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301151 · Cited by 74
Marenco, S., Egan, M. F., Goldberg, T. E., Knable, M. B., McClure, R. K., Winterer, G., & Weinberger, D. R. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00311-5 · Cited by 73
Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice
Brody, S. A., Conquet, F., & Geyer, M. A. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1635-3 · Cited by 71
Javitt, D. C., & Frusciante, M. J. (1997) · Psychopharmacology · doi:10.1007/s002130050168 · Cited by 70
Self-citationBalla, A., Koneru, R., Smiley, J., Sershen, H., & Javitt, D. C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00230-5 · Cited by 62
Self-citationProbing cortical dopamine function in schizophrenia: what can D1 receptors tell us?
Abi‐Dargham, A. (2003) · Europe PMC (PubMed Central) · Cited by 62
Makino, C., Fujii, Y., Kikuta, R., Hirata, N., Tani, A., Shibata, A., Ninomiya, H., Tashiro, N., Shibata, H., & Fukumaki, Y. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10041 · Cited by 59
Reynolds, L. M., Cochran, S. M., Morris, B., Pratt, J. A., & Reynolds, G. P. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.02.003 · Cited by 59
Swanson, C. J., & Schoepp, D. D. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038422 · Cited by 59
11. Neuropsychological deficits in the early course of first episode schizophrenia
Bilder, R. M., Lipschutz-Broch, L., Reiter, G., Stephen, G., Mayerhoff, D., & Lieberman, J. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90071-x · Cited by 57
Martina, M., B.‐Turcotte, M., Halman, S., Tsai, G. E., Tiberi, M., Coyle, J. T., & Bergeron, R. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.080655 · Cited by 56
Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors
Javitt, D. C., Hashim, A., & Sershen, H. W. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300589 · Cited by 53
Self-citationYurgelun-Todd, D. A., Coyle, J. T., Gruber, S. A., Renshaw, P. F., Silveri, M. M., AMICO, E. T., Cohen, B. M., & GOFF, D. C. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.11.006 · Cited by 52
Genetic mechanisms of psychosis: In vivo and postmortem genomics
Weinberger, D. R. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.016 · Cited by 50
Riley, B. P., Tahir, E., Rajagopalan, S., Mogudi-Carter, M., Fauré, S., Weissenbach, J., Jenkins, T., & Williamson, R. (1997) · Psychiatric Genetics · doi:10.1097/00041444-199722000-00002 · Cited by 46
Ghose, S., Weickert, C. S., Colvin, S. M., Coyle, J. T., Herman, M. M., Hyde, T. M., & Kleinman, J. E. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300304 · Cited by 46
van Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300902 · Cited by 43
Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case‐control study
Maria, E. D., Gulli, R., Begni, S., Luca, A. D., Bignotti, S., Pasini, A., Bellone, E., Pizzuti, A., Dallapiccola, B., Novelli, G., et al. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30028 · Cited by 40
Silent glutamatergic synapses in the mammalian brain
Isaac, J. T. R., Nicoll, R. A., & Malenka, R. C. (1999) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-77-9-735 · Cited by 38
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats
Clark, M., Johnson, B. G., Wright, R. A., Monn, J. A., & Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00848-1 · Cited by 37
Melone, M., Bragina, L., & Conti, F. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001193 · Cited by 34
Behavioral effects of chronic phencyclidine in monkeys
Linn, G. S., OʼKeeffe, R. T., Schroeder, C. E., Lifshitz, K., & Javitt, D. C. (1999) · NeuroReport · doi:10.1097/00001756-199909090-00017 · Cited by 34
Self-citationJentsch, D., Elsworth, J. D., Taylor, J. R., Redmond, D. E., & Roth, R. H. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60870-4 · Cited by 27
Inhibition of striatal dopamine release by glycine and glycyldodecylamide
Javitt, D. C., Sershen, H. W., Hashim, A., & Lajtha, Á. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00258-6 · Cited by 27
Self-citationJourdi, H., Lü, X., Yanagihara, T. K., Lauterborn, J. C., Bi, X., Gall, C. M., & Baudry, M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.083873 · Cited by 27
Flores, C., & Coyle, J. T. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300129 · Cited by 27
Peris, J., Dwoskin, L. P., & Zahniser, N. R. (1988) · Synapse · doi:10.1002/syn.890020413 · Cited by 25
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Self-citationGlutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“The NMDA receptor dysfunction hypothesis of schizophrenia arose initially from the observation that non-competitive NMDA receptor antagonists, including phencyclidine (PCP), dizocilpine (MK-801) and ketamine, lead to immediate psychological effects, which closely resemble symptoms that occur in schizophrenia, includin…”
Background
Metadata
- Authors
- Javitt, D. C.
- Venue
- International Review of Neurobiology
- Publisher
- Elsevier
- Published
- 2007
- Volume
- 78
- Pages
- 69-108
- ISSN
- 0074-7742 (ISSN-L)
- OpenAlex
- W1507804974
- Cited by
- 560
- References
- 205
- FWCI
- 123.63
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.